Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Immunotherapy Evolution Continues with Innovative Approaches to Multiple Myeloma Treatment
Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.
Related Clinical Trials:
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
The FDA approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD despite using inhaled medications, targeting patients with high eosinophil levels. Clinical trials showed Dupixent reduced moderate to severe COPD exacerbations by 14-22% compared to placebo, with similar side effect rates.
FDA Approves Dupixent for Patients with COPD
FDA approves Dupixent as add-on treatment for adults with uncontrolled COPD, marking the first biologic therapy for this condition. Dupixent, developed by Sanofi and Regeneron, targets type 2 inflammation pathways and has shown efficacy in reducing COPD exacerbations and improving lung function in phase 3 trials. The drug also has other approved uses and is being studied for bullous pemphigoid.
FDA Approves Selpercatinib For Pediatric and Adult Patients With RET-Mutated MTC
FDA approves selpercatinib (Retevmo) for advanced or metastatic medullary thyroid cancer (MTC) with RET mutation in adults and pediatric patients aged 2 years and older. The approval is based on the LIBRETTO-531 trial, showing selpercatinib's efficacy with progression-free survival (PFS) not reached compared to 16.8 months in the control arm. Selpercatinib's dosing varies by age and body surface area, with reduced severe side effects reported compared to other treatments.
Related Clinical Trials:
FDA Roundup: Agency Highlights from September 2024
FDA approves dupilumab for COPD, xanomeline and trospium chloride for schizophrenia, levacetylleucine for Niemann-Pick disease type C, FluMist for self-administered flu prevention, benralizumab for eosinophilic granulomatosis with polyangiitis, lebrikizumab-lbkz for atopic dermatitis, OTC hearing aid software for mild to moderate hearing loss, DaylightRX for generalized anxiety disorder, a disposable insulin patch pump for T1D and T2D, and an updated Novavax COVID-19 vaccine.
FDA Approves Dupixent as First Biologic Treatment for COPD
The FDA approved dupilumab (Dupixent) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, making it the first biologic medicine approved in the U.S. for this condition. The approval was based on two phase 3 studies, BOREAS and NOTUS, which demonstrated dupilumab's efficacy in reducing COPD exacerbations and improving lung function.
Related Clinical Trials:
Dupixent approved in the US as the first-ever biologic medicine for patients
Dupixent approved by FDA as the first biologic medicine for adults with inadequately controlled COPD and an eosinophilic phenotype, based on phase 3 studies showing significant reduction in exacerbations, improvements in lung function, and health-related quality of life.
FDA Approves Dupixent as First-Ever Biologic Treatment for Chronic Obstructive Pulmonary Disease
FDA approves Regeneron and Sanofi’s Dupixent as the first biologic treatment for adults with eosinophilic COPD, based on Phase III BOREAS and NOTUS trials showing significant reduction in exacerbations and improved lung function. Dupixent also improved quality of life and had a consistent safety profile.
FDA greenlights Regeneron's Dupixent for the treatment of COPD
FDA approves Regeneron and Sanofi's Dupixent for COPD, making it the first biologic treatment for the condition. Dupixent, an interleukin-4 receptor alpha antagonist, showed reduced exacerbations and improved lung function in Phase III studies. The approval follows failures of GSK's Nucala and AstraZeneca's Fasenra in COPD trials.
Related Clinical Trials:
Sanofi/Regeneron's Dupixent set to dominate COPD biologics market following FDA approval
FDA approves Sanofi and Regeneron’s Dupixent for COPD, showing significant reduction in exacerbations and improved lung function in Phase III trials. Expected to dominate COPD biologics market with projected sales of $6.57bn by 2033.
© Copyright 2025. All Rights Reserved by MedPath